TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality

被引:0
作者
Jue Wang
Tongjuan Li
Mi Zhou
Zheng Hu
Xiaoxi Zhou
Shiqiu Zhou
Na Wang
Liang Huang
Lei Zhao
Yang Cao
Min Xiao
Ding Ma
Pengfei Zhou
Zhen Shang
Jianfeng Zhou
机构
[1] Tongji Hospital,Department of hematology
[2] Tongji Medical College,Cancer Biology Research Center
[3] Huazhong University of Science and Technology,undefined
[4] Tongji Hospital,undefined
[5] Tongji Medical College,undefined
[6] Huazhong University of Science and Technology,undefined
[7] Wuhan YZY Bio-Pharma Co.,undefined
[8] Ltd.,undefined
来源
Scientific Reports | / 5卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Novel analytic tools are needed to elucidate the molecular basis of leukemia-relevant gene mutations in the post-genome era. We generated isogenic leukemia cell clones in which the FLT3 gene was disrupted in a single allele using TALENs. Isogenic clones with mono-allelic disrupted FLT3 were compared to an isogenic wild-type control clone and parental leukemia cells for transcriptional expression, downstream FLT3 signaling and proliferation capacity. The global gene expression profiles of mutant K562 clones and corresponding wild-type controls were compared using RNA-seq. The transcriptional levels and the ligand-dependent autophosphorylation of FLT3 were decreased in the mutant clones. TALENs-mediated FLT3 haplo-insufficiency impaired cell proliferation and colony formation in vitro. These inhibitory effects were maintained in vivo, improving the survival of NOD/SCID mice transplanted with mutant K562 clones. Cluster analysis revealed that the gene expression pattern of isogenic clones was determined by the FLT3 mutant status rather than the deviation among individual isogenic clones. Differentially expressed genes between the mutant and wild-type clones revealed an activation of nonsense-mediated decay pathway in mutant K562 clones as well as an inhibited FLT3 signaling. Our data support that this genome-editing approach is a robust and generally applicable platform to explore the molecular bases of gene mutations.
引用
收藏
相关论文
共 75 条
[1]  
Pui CH(2008)Acute lymphoblastic leukaemia Lancet 371 1030-1043
[2]  
Robison LL(2012)How to manage high-risk acute myeloid leukemia Leukemia 26 861-869
[3]  
Look AT(2011)Genomics of AML: clinical applications of next-generation sequencing Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2011 30-35
[4]  
Estey EH(2013)Next generation sequencing: new tools in immunology and hematology Blood research 48 242-249
[5]  
Welch JS(2013)Modeling human disease with pluripotent stem cells: from genome association to function Cell stem cell 12 656-668
[6]  
Link DC(2010)The evolution of cancer modeling: the shadow of stem cells Disease models & mechanisms 3 149-155
[7]  
Mori A(2010)Targeting DNA double-strand breaks with TAL effector nucleases Genetics 186 757-761
[8]  
Merkle FT(2011)A TALE nuclease architecture for efficient genome editing Nature biotechnology 29 143-148
[9]  
Eggan K(2013)TALENs: a widely applicable technology for targeted genome editing Nature reviews. Molecular cell biology 14 49-55
[10]  
Vicente-Duenas C(2014)Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing Nature biotechnology 32 941-946